On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth ...

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses lately. However, the stock is currently experiencing an uptrend in its price performance. The San Francisco, ...

The hire comes as the San Francisco company expands globally, including its recent purchase of an Australian telehealth firm ...

Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate ...

Hims & Hers Health Inc HIMS shares are climbing in Thursday's premarket session. This follows a double-digit gain during ...

Consumers are paying in cash in a hotly competitive marketplace, creating a rare phenomenon for a relatively new class of prescription drugs: falling prices.

Check out the companies making headlines before the bell. Bumble — Bumble shares popped about 21% after the dating app ...

Investing.com -- Hims & Hers Health shares climbed as much as 7.2% in premarket trading on Thursday, following a 10% rally on Wednesday. The stock is set to extend its advance for a fourth straight ...

Artificial intelligence cloud provider Nebius Group (NBIS) is trending on Thursday, after shares jumped following the announcement that chipmaker Nvidia (NVDA) will invest $2bn (£1.49bn) in the ...